hemagglutin
inhibit
abil
immun
serum
block
clump
red
blood
cell
caus
crosslink
cell
multival
virus
receptor
red
blood
cell
surfac
antigen
heterotyp
abl
recogn
one
viru
serotyp
jennerian
vaccin
approach
anim
viru
use
protect
human
diseas
reassort
exchang
gene
segment
virus
multipartit
genom
coinfect
split
vaccin
vaccin
antigen
chemic
disrupt
viru
particl
subunit
vaccin
vaccin
antigen
purifi
viru
microb
compon
tolllik
receptor
type
receptor
recogn
conserv
microbi
compon
trigger
innat
immun
respons
undergo
splice
recombin
gener
divers
viremia
presenc
viru
blood
vaccin
use
today
result
empir
develop
mechan
action
mani
vaccin
common
use
remain
incomplet
understood
understand
vaccin
protect
ongo
subject
studi
use
increasingli
sophist
immunolog
tool
b
cell
cell
repertoir
transcriptom
analysi
tool
also
appli
design
vaccin
viral
target
evad
vaccinemedi
protect
thu
far
basic
immunolog
scienc
intersect
practic
assur
vaccin
safeti
toler
efficaci
consist
clinic
practic
util
sophist
immunolog
measur
vaccin
develop
may
determin
whether
reduc
simpli
execut
highli
standard
reproduc
assay
outcom
clear
interpret
vaccin
develop
use
basic
immunolog
empir
vaccin
test
regulatori
scienc
necessari
contributor
develop
next
gener
vaccin
includ
vaccin
effect
pathogen
vaccin
current
avail
immun
virus
achiev
greatest
success
medicin
erad
smallpox
worldwid
control
polio
world
yet
major
viral
pathogen
human
immunodefici
viru
hiv
hepat
c
viru
hcv
respiratori
syncyti
viru
rsv
human
cytomegaloviru
effect
vaccin
avail
despit
decad
research
develop
tabl
list
viral
agent
licens
vaccin
avail
unit
state
singular
except
virus
show
limit
antigen
divers
undergon
littl
antigen
chang
time
except
influenza
viru
defin
current
limit
abil
immun
effect
face
substanti
antigen
divers
chang
list
vaccin
develop
use
tool
modern
molecular
biolog
sophist
immunolog
method
mani
vaccin
antigen
vaccin
influenza
viru
japanes
enceph
viru
rabi
viru
polioviru
produc
grow
virus
chemic
inactiv
viral
vaccin
produc
propag
live
virus
attenu
experiment
passag
cultur
nonhuman
host
influenza
viru
yellow
fever
viru
measl
viru
mump
viru
rubella
viru
use
viru
strain
origin
nonhuman
host
jennerian
vaccinesrotaviru
vaccinia
viru
nonrecombin
genet
manipul
genom
segment
reassort
coinfect
rotaviru
influenza
viru
prepar
vaccin
still
use
influenza
viru
yellow
fever
viru
produc
viru
propag
fertil
chicken
egg
rather
cell
cultur
except
gener
low
technolog
approach
produc
vaccin
antigen
includ
recombinantli
produc
vaccin
antigen
hepat
b
viru
hbv
human
papillomaviru
hpv
influenza
viru
hpv
hbv
vaccin
antigen
express
yeast
insect
cell
selfassembl
particl
resembl
releas
virusinfect
cell
zeltin
similarli
vaccin
use
today
either
unadjuv
adjuv
alum
use
enhanc
immun
respons
vaccin
sinc
baylor
et
al
except
one
licens
hpv
vaccin
includ
tolllik
receptor
agonist
adjuv
base
monophosphoryl
lipid
mpl
influenza
vaccin
avail
european
union
countri
includ
oilinwat
emuls
adjuv
del
giudic
rappuoli
garcon
et
al
vaccin
complex
mechan
action
almost
pharmaceut
product
rather
act
directli
welldefin
singl
ligandreceptor
interact
vaccin
antigen
adjuv
seri
complex
interact
multipl
compon
immun
system
near
site
immun
sometim
system
site
well
interact
prime
host
anamnest
respons
subsequ
infecti
challeng
often
anoth
anatom
site
host
time
remot
immun
antigen
viral
challeng
may
differ
vaccin
case
host
may
experienc
infect
antigen
relat
viru
prior
immun
ad
addit
element
complex
vaccin
immun
respons
complex
immunolog
underli
protect
diseas
immun
make
fascin
subject
scientif
investig
howev
practic
vaccin
develop
straightforward
definit
easili
execut
reproduc
readili
interpret
immunolog
assay
need
character
defin
respons
vaccin
fulli
intersect
rich
complex
vaccin
immunolog
practic
need
simplic
regulatori
scienc
contribut
gap
scienc
practic
vaccinolog
vaccin
simpl
model
determin
protect
proven
suffici
practic
decis
make
exampl
hbv
vaccin
elicit
postvaccinationbind
titer
hbv
surfac
antigen
sag
miuml
subject
consid
protect
jack
et
al
even
antisag
titer
fall
miuml
miuml
substanti
level
protect
persist
west
calandra
similarli
yellow
fever
vaccin
plaqu
neutral
serum
antibodi
titer
neutral
index
equival
differ
titer
log
preand
postvaccin
serum
strongli
associ
protect
mason
et
al
neutral
viru
antibodi
gener
consid
domin
mode
protect
virus
whose
pathogenesi
requir
viremia
exampl
includ
polioviru
smallpox
viru
yellow
fever
viru
hbv
varicella
zoster
viru
chicken
pox
zoster
measl
viru
mump
viru
rubella
viru
like
oversimplif
true
situat
prove
use
simplif
vaccin
develop
monitor
plotkin
assign
reliabl
correl
protect
challeng
vaccin
virus
predominantli
infect
replic
mucos
surfac
inactiv
influenza
vaccin
serum
hemagglutin
inhibit
hi
titer
long
accept
correl
protect
base
primarili
studi
young
adult
de
jong
et
al
howev
consider
higher
antibodi
level
may
requir
protect
children
hi
titer
confer
protect
immun
adjuv
inactiv
influenza
vaccin
black
et
al
elderli
measur
cellmedi
immun
granzym
b
level
virusstimul
peripher
blood
mononuclear
cell
may
correl
better
serum
antibodi
titer
vaccineelicit
protect
mcelhaney
et
al
addit
correl
protect
immun
inactiv
influenza
vaccin
predict
protect
immun
live
attenu
influenza
vaccin
offer
protect
would
predict
base
elicit
serum
hi
neutral
titer
beyer
et
al
whether
cellmedi
effector
mechan
mucos
antibodi
factor
primarili
respons
protect
live
attenu
influenza
vaccin
natur
infect
remain
controversi
despit
sever
decad
studi
reliabl
correl
protect
even
elus
rotaviru
caus
diarrhea
infect
small
intestin
epithelium
base
studi
anim
model
homotyp
neutral
antibodi
thought
play
key
role
protect
make
viral
serotyp
import
distinct
yet
human
monoval
live
attenu
rotaviru
vaccin
provid
substanti
heterotyp
protect
leshem
et
al
number
candid
mechan
greater
breadth
protect
includ
heterotyp
neutral
antibodi
heterotyp
nonneutr
antibodi
block
intracellular
replic
cellmedi
effector
mechan
mechan
wide
accept
respons
cellmedi
effector
mechan
thought
play
signific
role
vaccinemedi
protect
virus
varicella
zoster
viru
adult
influenza
viru
live
attenu
vaccin
forrest
et
al
weinberg
et
al
elicit
effect
helper
th
respons
essenti
mount
affinitymatur
durabl
humor
respons
vaccin
control
changeabl
virus
har
cellmedi
effector
mechan
prevent
viral
diseas
human
therefor
two
chief
challeng
modern
vaccinolog
increasingli
sophist
tool
b
cell
repertoir
analysi
transcriptom
analysi
advanc
function
imag
use
understand
vaccin
mechan
action
tsang
et
al
jiang
et
al
karlsson
et
al
yet
case
technolog
use
manufactur
current
human
vaccin
core
immunoassay
use
bring
viral
vaccin
licensur
gener
simpl
exemplifi
antibodybas
viral
neutral
assay
enzymelink
immunosorb
assay
multiplex
bind
assay
restrict
rang
assay
type
larg
reflect
need
standard
assay
rigor
guidanc
industri
bioanalyt
method
valid
draft
practic
limit
sophist
assay
use
primari
endpoint
largescal
clinic
trial
often
ten
thousand
subject
requir
bring
novel
vaccin
licensur
sophist
measur
cellmedi
immun
promin
role
vaccin
research
much
minor
role
vaccin
licensur
difficulti
standard
assay
assign
threshold
assay
valu
indic
protect
limit
use
correl
protect
vaccin
trial
use
registr
similarli
although
mucos
immun
sure
play
major
role
determin
vaccinemedi
protect
challeng
sampl
collect
assay
consist
consequ
serum
antibodi
level
rather
measur
mucos
immun
favor
correl
protect
vaccin
licensur
nevertheless
measur
cellmedi
immun
enzymelink
immunosorb
spot
assay
fluorescenceactiv
cell
sorterbas
cell
function
analys
routin
use
exploratori
endpoint
vaccin
develop
recent
investig
also
ad
system
biolog
approach
transcript
array
mass
cytometrybas
cell
sort
luminex
bind
assay
analyt
tool
box
investig
earli
innat
immun
respons
vaccin
ogorman
et
al
tsang
et
al
date
none
interest
approach
proven
suffici
robust
predict
use
licensur
criteria
standard
assay
could
lead
promin
role
assay
cellmedi
mucos
innat
immun
vaccin
develop
antigen
divers
antigen
chang
remain
key
challeng
develop
effect
vaccin
sever
import
agent
influenza
vaccin
must
chang
composit
almost
annual
basi
track
antigen
drift
shift
vaccin
vari
consider
effect
year
year
depend
part
accuraci
antigen
match
vaccin
circul
strain
pathogen
variabl
influenza
hiv
hcv
attempt
immun
thu
far
proven
larg
ineffect
despit
identif
viral
target
broadli
neutral
antibodi
burton
mascola
kong
et
al
throsbi
et
al
whittl
et
al
evas
vaccinemedi
immun
exampl
replic
privileg
reservoir
pose
anoth
challeng
vaccin
develop
hiv
evad
vaccinemedi
immun
select
resist
variant
respons
immun
pressur
also
replic
immuneprivileg
site
cell
central
nervou
system
churchil
nath
latenc
herp
virus
pose
challeng
vaccin
develop
though
insurmount
challeng
evid
efficaci
varicella
zoster
vaccin
reactiv
diseas
shingl
lal
et
al
oxman
et
al
durat
immun
elicit
viral
vaccin
also
vari
best
case
singl
immun
live
attenu
yellow
fever
vaccin
appear
confer
lifelong
protect
although
current
recommend
booster
everi
year
risk
gotuzzo
et
al
extrem
need
annual
immun
influenza
appear
sole
due
antigen
chang
circul
virus
durat
immun
elicit
nonadjuv
inactiv
influenza
vaccin
appear
limit
vaccin
strainspecif
effect
decreas
cours
season
account
antigen
drift
circul
virus
kissl
et
al
pebodi
et
al
special
popul
pose
particular
challeng
viral
vaccin
neonat
respons
immun
differ
respons
later
life
preferenti
elicit
memori
b
cell
rather
plasma
cell
cell
respons
wood
siegrist
passiv
transfer
matern
antibodi
interfer
vaccin
immunogen
particularli
infant
month
age
crow
safeti
critic
issu
neonat
immun
exampl
find
excess
wheez
hospit
prevent
live
attenu
influenza
vaccin
use
infant
year
age
despit
util
older
children
prutski
et
al
overcom
factor
take
advantag
primeboost
effect
infant
immun
gener
carri
multipl
dose
often
includ
remot
booster
rsv
major
caus
infant
diseas
current
licens
vaccin
insuffici
time
elicit
activ
immun
respons
peak
incid
sever
diseas
approxim
month
age
earli
peak
diseas
chief
rational
underli
propos
matern
immun
rsv
anderson
et
al
immun
pregnant
women
increas
level
pathogenspecif
antibodi
transfer
transplacent
breast
milk
newborn
immun
pregnant
women
gain
increas
accept
part
due
experi
immun
pregnant
women
influenza
pandem
caus
disproportion
sever
ill
pregnant
women
fell
et
al
evid
improv
birth
outcom
influenza
immun
pregnanc
steinhoff
et
al
success
matern
immun
prevent
neonat
tetanu
blencow
et
al
end
age
spectrum
immun
senesc
creat
challeng
immun
elderli
highdos
formul
inactiv
influenza
vaccin
varicella
zoster
vaccin
adjuv
formul
inactiv
influenza
vaccin
use
increas
vaccin
effect
elderli
diazgranado
et
al
mannino
et
al
oxman
et
al
immunodefici
also
pose
challeng
immun
exampl
renal
failur
patient
hemodialysi
particular
risk
acquisit
hepat
b
yet
hbv
vaccin
less
like
elicit
protect
antibodi
titer
popul
led
licensur
hepat
b
vaccin
adjuv
mplanalog
adsorb
aluminum
phosphat
renal
insuffici
european
union
kundi
also
safeti
concern
around
use
live
attenu
vaccin
immunodefici
live
attenu
vaccin
target
smallpox
viru
yellow
fever
viru
rotaviru
caus
clinic
ill
due
infect
attenu
vaccin
viru
immunodefici
bakar
et
al
reed
et
al
seligman
potenti
vaccinemedi
diseas
enhanc
substanti
hinder
develop
rsv
vaccin
anderson
et
al
formalininactiv
rsv
vaccin
candid
prime
immun
infant
sever
rsv
diseas
upon
natur
rsv
challeng
kapikian
et
al
preponder
evid
suggest
immunopatholog
cellular
respons
coupl
minim
neutral
antibodi
respons
vaccin
respons
enhanc
diseas
although
mechan
vaccinemedi
diseas
enhanc
still
complet
understood
graham
observ
vaccineenhanc
diseas
also
made
human
immun
inactiv
measl
vaccin
fulgin
et
al
ferret
model
experiment
immun
sever
acut
respiratori
syndrom
coronaviru
weingartl
et
al
evid
preced
comment
ampl
opportun
appli
stateoftheart
immunolog
well
modern
manufactur
practic
vaccin
remain
larg
gap
larg
divers
immun
approach
research
earli
develop
limit
applic
new
scienc
technolog
vaccin
licens
latestag
develop
part
reflect
challeng
replac
suffici
effect
old
vaccin
new
one
old
vaccin
long
track
record
safe
administr
new
vaccin
knowledg
safeti
efficaci
effect
necessarili
limit
matter
theoret
advantag
new
technolog
may
offer
addit
mani
old
establish
vaccin
still
use
remark
inexpens
undermin
econom
would
permit
replac
much
expens
new
vaccin
burden
new
develop
cost
nevertheless
key
viral
pathogen
hiv
rsv
cmv
herp
simplex
viru
dengu
viru
hcv
resist
success
vaccin
develop
use
convent
techniqu
prime
target
innov
approach
sophist
applic
immunolog
vaccin
develop
could
address
challeng
clinic
develop
vaccin
exampl
increas
use
immunolog
marker
vaccin
safeti
immunogen
efficaci
could
limit
clinic
trial
size
durat
intens
studi
smaller
number
subject
earli
clinic
trial
could
lead
test
vaccin
candid
better
inform
decis
whether
progress
vaccin
candid
largerscal
clinic
test
switch
promis
altern
vaccin
candid
rappuoli
aderem
exampl
cell
respons
observ
week
immun
influenza
vaccin
predict
neutral
antibodi
respons
month
immun
potenti
enabl
rapid
answer
immunogen
clinic
trial
vaccin
galli
et
al
although
analysi
biomark
sophist
immunolog
analys
may
enhanc
abil
assess
aspect
vaccin
safeti
immunogen
smaller
trial
less
like
approach
enabl
detect
unanticip
idiosyncrat
advers
event
larg
phase
iii
trial
postlicensur
surveil
design
detect
exampl
idiosyncrat
event
includ
guillainbarr
syndrom
observ
influenza
immun
follow
swine
flu
outbreak
schonberg
et
al
narcolepsi
associ
pandem
influenza
vaccin
northern
european
adolesc
ahm
et
al
intestin
intussuscept
associ
greater
lesser
degre
differ
live
attenu
rotaviru
vaccin
rosillon
et
al
howev
core
set
safeti
immunogen
paramet
could
assess
smaller
trial
intens
studi
immunolog
biomark
burden
detect
rare
event
could
shift
larg
prelicensur
trial
postlicensur
surveil
system
decreas
barrier
advanc
vaccin
licensur
meet
unmet
medic
need
b
cell
repertoir
analysi
provid
wealth
new
inform
divers
antibodi
collect
make
serum
antibodi
respons
vaccin
key
find
among
neutral
antibodi
elicit
respons
influenza
viru
hiv
rsv
infect
immun
remark
broad
specif
burton
mascola
corti
et
al
corti
et
al
date
b
cell
repertoir
analysi
coupl
function
analysi
antibodi
structur
analysi
antigenantibodi
complex
defin
antibodi
want
vaccin
elicit
target
structur
virus
recogn
antibodi
progress
also
made
abil
design
epitopefocus
antigen
elicit
antibodi
correia
et
al
schickli
et
al
howev
date
engin
antigen
proven
effect
elicit
high
titer
broadli
neutral
antibodi
intact
glycoprotein
domain
contain
epitop
interest
iter
improv
ration
design
antigen
howev
hold
promis
improv
vaccin
target
patch
conserv
variabl
multiepitop
antigen
vaccin
base
conserv
cell
epitop
intern
protein
antigen
target
cellbas
effector
mechan
area
activ
research
theoret
vaccin
target
conserv
nonsurfac
protein
virus
express
infect
cell
could
overcom
antigen
divers
surfac
neutral
determin
exampl
small
human
live
viral
challeng
studi
vector
express
influenza
intern
matrix
protein
nucleoprotein
togeth
significantli
reduc
number
day
viru
shed
laboratoryconfirm
influenza
infect
lilli
et
al
remain
determin
whether
mechan
protect
prove
effect
durabl
enough
primari
basi
vaccinemedi
protect
howev
even
absent
abil
suffic
primari
basi
influenza
vaccin
conserv
target
cell
effector
may
prove
use
supplement
increas
breadth
coverag
vaccin
also
includ
target
potent
protect
strainspecif
humor
immun
antrobu
et
al
cell
effector
mechan
involv
kill
host
cell
prime
increas
effector
respons
carri
risk
exacerb
diseas
even
acceler
viral
clearanc
increas
insight
innat
immun
mechan
inform
search
new
gener
ration
design
adjuv
adjuv
current
licens
vaccin
aluminum
salt
oilinwat
emuls
mplanalog
product
larg
empir
develop
effort
ohagan
fox
elucid
tolllik
receptor
key
sentri
molecul
detect
potenti
pathogen
recruit
antigenpres
cell
subsequ
antigenspecif
respons
enabl
ration
design
new
gener
potenti
vaccin
adjuv
wu
et
al
use
wellestablish
principl
smallmolecul
screen
optim
ligand
bind
new
tolllik
receptor
agonist
reach
clinic
test
similarli
abil
target
vaccineprim
respons
mucos
tissu
use
retino
acid
adjuv
thu
far
demonstr
preclin
test
provid
addit
mode
action
adjuv
shape
charact
vaccinemedi
immun
respons
tan
et
al
import
note
howev
demonstr
safeti
especi
appli
rare
idiosyncrat
event
remain
critic
hurdl
licensur
vaccin
contain
novel
adjuv
larg
empir
approach
vaccin
develop
provid
tremend
public
health
benefit
understand
vaccin
immunolog
advanc
greatli
sinc
mani
vaccin
still
use
origin
develop
appli
new
knowledg
could
improv
current
vaccin
lead
develop
vaccin
viral
diseas
resist
vaccinemedi
protect
date
